





FIG. 1





BINDING INHIBITION

















FIG. 5B




FIG.5C

## INTERLEUKINE-2 RECEPTOR







FIG. 6A


USSN


FIG. 6B








































ACTIVITY	<b>+</b>	#	1	1	1	8	+	
MAIN MOLECULAR SPECIES	IETRAMER (4M-8M, Kd=30-100 pM) /OCTAMER	DIMER (1M-2M,Kd=0,2µM) /TETRAMER (2M-4M,Kd=100µM)		(1M-2M,Kd=50µM) (2M-4M,Kd=1,4mM)	(1M-2M,Kd=113µM)	æ	85	
MAIN M	TETRAMER ( /OCTAMER	DIMER /Tetrai		DIMER	DIMER	MONOMER	MONOMER	
% HELIX (CIRCULAR DICHROISM)	50% (150 @ 30µM) 35% (4µM)	22% (150 @ 30µM)	<2%	<b>%</b> 0	%0	%0	<b>~5%</b>	
10 20 30 TTSSSTKKTQLQLEHLLLDLQMILNGINN	30	10 30	22	<u> </u>	15	10 20	20 20	
1 PTTSSSTK		<b></b>			2			



IP130

## FIG. 11A




IP130

FIG. 11B

(


## BLOT 4G10 (ANTI PHOSPHOTYROSINE)




NO STIMULATION IL-2 (IO MIN)

IP 130(1 MIN )
IP 130(2 MIN)
IP 130(5 MIN)
IP 130(15 MIN)


F I G .12 A






ACTIVATED STATS

9 FIG.13






## NK CELLS (CD56 $^+$ ) ENTERING IN S+G2/M PHASES AFTER IP130 STIMULATION (SYNERGY WITH IL-2)

TREATMENT					J31	J32	J33	
			·	. · · ·				
IL-2 50 nM				. 1	14	12	14	
		IP130	60 <i>µ</i> M	(	)	17	<b>≤</b> 5	
		IP130	120µM	0	)	14	<5	
IL-2 50 nM	+	IP130	60µM	2	26	21	7	
IL-2 50 nM	+	IP130	120µM	2	28	28	28	

FIG. 15







FIG. 164

STIMULATION 6 DAYS

9

8







8


SISJ7% V


\$

2












FIG. 19